SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a - 16 OR 15d - 16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of May, 2007
SkyePharma PLC
SkyePharma PLC, 105 Piccadilly, London W1J 7NJ England
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40F.
Form 20-F X Form 40-F
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes No X
If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- _______
SkyePharma PLC Announces Results of Shareholder Vote and Grant of Awards
under the New Long-Term Incentive Plan
LONDON, UK, 4 May 2007 - SkyePharma PLC (the "Company") (LSE: SKP; Nasdaq: SKYE) announces the results of the voting by shareholders
at the Extraordinary General Meeting held earlier today. The resolution approving the SkyePharma PLC 2007 Long-Term Incentive Plan
(the "LTIP") was passed.
The Remuneration Committee has granted the following conditional nil cost share awards to the Executive Directors under the
SkyePharma PLC 2007 Long-Term Incentive Plan.
In accordance with the rules of the LTIP, LTIP awards were granted on 4 May 2007 at a price of 23 pence per Ordinary Share (the
closing share price on the preceding dealing day) as follows:
Executive Director Number of Ordinary Shares subject to the
LTIP Award at a price of 23 pence per
Ordinary Share
Frank Condella (CEO) 5,869,565
Dr Ken Cunningham (COO) 3,260,869
Peter Grant (FD) 2,739,130
The Ordinary Shares subject to LTIP awards will only be released to the directors in three years time subject to their continued
employment and the satisfaction of the following conditions:-
- 10% of the Ordinary Shares subject to LTIP awards will be released if the Company's share price is 35 pence at the end of
the three year period with 100% released for a share price of 55 pence;
- the Remuneration Committee will also be ensuring that the underlying financial performance of the Company is consistent with
its share price performance.
For further information please contact:
---------------------------------------------------------------------------------------------------------
SkyePharma PLC
---------------------------------------------------------------------------------------------------------
Frank Condella, Chief Executive Officer
---------------------------------------------------------------------------------------------------------
Ken Cunningham, Chief Operating Officer +44 207 491 1777
---------------------------------------------------------------------------------------------------------
Peter Grant, Finance Director
---------------------------------------------------------------------------------------------------------
---------------------------------------------------------------------------------------------------------
Financial Dynamics (London enquiries)
---------------------------------------------------------------------------------------------------------
David Yates / Deborah Scott +44 207 831 3113
---------------------------------------------------------------------------------------------------------
---------------------------------------------------------------------------------------------------------
Trout Group (US enquiries)
---------------------------------------------------------------------------------------------------------
Christine Labaree / Seth Lewis +1 617 583 1308
---------------------------------------------------------------------------------------------------------
About SkyePharma PLC
Using its proprietary drug delivery technologies, SkyePharma develops new formulations of known molecules to provide a clinical
advantage and life-cycle extension. The Group has ten approved products in the areas of oral, inhalation and topical delivery. The
Group's products are marketed throughout the world by leading pharmaceutical companies. For more information, visit
www.skyepharma.com.
END
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
SkyePharma PLC
By: /s/ John Murphy
Name: John Murphy
Title:
Company Secretary
Date: May 04, 2007